dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Pöördumine

Sotsiaalministeerium · 14. juuni 2021
Viit
1.4-4/1971-1
Registreeritud
14. juuni 2021
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-4 Kutsed ja kirjavahetus rahvusvahelistel seminaridel, konverentsidel jt üritustel osalemiseks
Toimik
1.4-4/2021
Vastutaja
Katrin Tomson-Johanson (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)
Lahendamise tähtaeg
30. juuni 2021

Failid

  • 📎C.L.20.2021 (44th ECDD).pdf512 KB
  • 📎E-kiri.pdf66 KB

Sisu (failidest)

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW. WHO.INT Ref.: C.L.20.2021 The World Health Organization (WHO) presents its compliments to Member States and Associate Members and has the pleasure of announcing that the 44th Expert Committee on Drug Dependence (ECDD) will meet from 11 to 15 October 2021, coordinated from Geneva, Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this letter serves to notify Member States of the substances under review at the 44th ECDD, which are in … the Annex I, attached for reference. WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make recommendations to the UN Secretary-General on the need for and level of international control of psychoactive substances based on the advice of its independent scientific advisory body, the ECDD. To assess the appropriate control of a psychoactive substance, the ECDD convenes annually to review the potential of this substance to cause dependence, abuse and harm to health, as well as any therapeutic applications. In order to perform this review and make scientific and evidence-based decisions, the ECDD conducts medical, scientific, and public health evaluations of the selected psychoactive substances using the best available information. Although the meetings are of a closed nature, Member States are invited to contribute to the ECDD review process by joining the 44th ECDD Information Session on 11 October 2021. The Information Session will allow interested parties to learn about present and future activities of the ECDD Secretariat, and to present information concerning substances under review to the Expert Committee. Registration information will be made available on the ECDD web site in due course: https://www.who.int/medicines/access/controlled-substances/en/. As in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6) 1, Member States can also contribute to the ECDD review process by providing up to date and accurate information concerning the substances under review in advance of the meeting. For this purpose, and as per previous practice, a questionnaire will be sent to Member States to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation. … Annex II to this Circular Letter contains a list of national focal points officially designated by Member States in previous years who provide country information to the ECDD through the Member States questionnaire referred to above. If the focal point information requires changes or amendments, Member States are invited to inform the WHO ECDD Secretariat by email to 1 http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=58. ... ENCLS: (2) Page 2 C.L.20.2021 [email protected] by 1 July 2021 with the subject “44ECDD Focal Point: (Country Name)”. If the individual on the list is still the official focal point for completing the ECDD Member State questionnaire this year and if no additions or amendments to focal point details are made by 1 July 2021, the focal point from the list will be given further instructions and direct access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be prepared as a report as part of the 44th ECDD substance review process. In addition to the questionnaire, Member States are also encouraged to provide any additional relevant information (unpublished or published) on substances to be reviewed by the 44th ECDD by emailing [email protected] with the subject “Ref: C.L.20.2021”. The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration. GENEVA, 10 June 2021 Annex I 44rd Expert Committee on Drug Dependence (ECDD) 11–15 October 2021 Substances for review Critical reviews: The substances listed below have never been formally reviewed by WHO and are not currently under international control. Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially serious risk to public health and society, and of no recognised therapeutic use by any Party. The Expert Committee will consider whether information presented during a critical review may justify the scheduling or a change in the scheduling of the substance in the 1961 or 1971 Conventions. Synthetic cannabinoid receptor agonists 1. 4F-MDMB-BICA (4F-MDMB-BUTICA) Novel synthetic opioids 2. Brorphine 3. Metonitazene Cathinones/stimulants 4. Eutylone (bk-EBDB) 5. BMDP (3,4-Methylenedioxy-N-benzylcathinone), benzilone Pre-reviews: The substances listed below have been proposed for a pre-review. The purpose of a pre-review is to determine whether current information justifies an Expert Committee critical review. A pre-review is a preliminary analysis and findings at this stage should not determine whether the control status of a substance should be changed. Herbal drugs 1. Kratom, mitragynine, 7-hydroxymitragynine Medicines 2. Phenibut Annex 2 List of focal points designated by Member States in previous years Country Name Focal Point E-mail Affiliation Position Afghanistan Shahpoor Yousuf [email protected] Regulation Sector of Regulation Sector of Albania Linda Ternova [email protected] Pharmaceutical Market and Pharmaceutical Market and Medical Devices Medical Devices Chargé du dossier des stupéfiants, des Algeria Ghrieb Houria [email protected] psychotropes et des précurseurs chimiques Department of Health Andorra Carla Lobaco Valls [email protected] Technical officer Resources and Medicines Department of Health Andorra Carme Pallarés Papaseit [email protected] Chief Resources and Medicines Angola Antigua and Barbuda Administración Nacional de Argentina G. Rebaldería [email protected] Medicamentos, Alimentos y Psicotrópicos Tecnología Controlled Substances Armenia Hasmik Martirosyan [email protected] Head Management Department Australia Allison Jones [email protected] UN Health Section, International and Commonwealth/State Australia Leila Jordan [email protected] Director Relations Branch, Australian Government Department of Health Austria Raphael Bayer [email protected] Telman Suleyman Oglu Azerbaijan [email protected] Mammadhassanov 1 Annex 2 Country Name Focal Point E-mail Affiliation Position Bahamas Bahrain Samar Yousef Salem [email protected] Addl. Secretariat, Health Md. Habibur Rahman Bangladesh [email protected] Services Division, Ministry of Khan Health and Family Welfare Barbados Maryam Hinds [email protected] Barbados Drug Service Организационно- методический отдел, государственное Заведующий сектором Belarus Инна Белаец [email protected] учреждение наркологии “Республиканский научно- практический центр психического здоровья” Epidemiology and public Belgium Peter Blankaert [email protected] Director health Belize Direction de la Pharmacie, du Benin Hope Akohouvi Amou [email protected] Médicament et des Pharmacien Diplômé d’Etat Explorations Diagnostiques Bhutan Dil Kumar Subba [email protected] Bolivia (Plurinational State of) Maria Julia Carrasco [email protected] Bosnia and Herzegovina Ana Cvijanović [email protected] Bosnia and Herzegovina Sabina Šahman [email protected] Department of Clinical Botswana Vivian Sebako [email protected] Chief Pharmacist Services Maria Dilma Alves Brazil [email protected] Teodoro National Health Surveillance Controlled products Brazil Renata de Morais Souza [email protected] Agency (Anvisa) manager Brazil [email protected] 2 Annex 2 Country Name Focal Point E-mail Affiliation Position Director of Pharmaceutical Brunei Darussalam Hajah Rosni Haji Jair [email protected] Services Health Promotion and Bulgaria Slaveyka Nikolova [email protected] Prophylaxis of Diseases and Senior Expert Addictions National Focal Centre in the Bulgaria [email protected] National Centre of Narcotic Director Addictions Ouedraogo Soutongo Sita Agence Nationale de Burkina Faso [email protected] Pharmacien Sandrine Régulation Pharmaceutique Burundi Aimable Bizoza [email protected] Entidade Reguladora Director of the Cabo Verde Lenira Centeio [email protected] Independente da Saúde Pharmacuetical Regulation (ERIS) Directorate Entidade Reguladora Technician of the Cabo Verde Cheila Barros [email protected] Independente da Saúde Pharmaceutical Regulation (ERIS) Directorate Member of the Board Entidade Reguladora Direction of ERIS, Cabo Verde Íris de Vasconcelos Matos [email protected] Independente da Saúde responsable for the (ERIS) pharmaceutical area Cambodia Chhit Sophal [email protected] Cameroon Ketchozo Loko Wilfried [email protected] Canada [email protected] Central African Republic Chad Haoua Haroun Saker [email protected] Department of Mental Health. Advisor for the Department Chile Alejandro Riquelme [email protected] Ministry of Health of Chile of Mental Health Department of Mental Health. Chile Pablo Norambuena [email protected] Mental Health Advisor Ministry of Health of Chile 3 Annex 2 Country Name Focal Point E-mail Affiliation Position Department of Mental Health. Head of the Mental Health Chile Matias Irarrazaval [email protected] Ministry of Health of Chile Department National Narcotics Deputy Director of Division China Hua Zhendong [email protected] Laboratory II Office of National Narcotics Officers from International China Wang Wei [email protected] Control Commission Cooperation Division National Narcotics China Xu Peng [email protected] Senior Expert Laboratory Colombia Oscar Ricardo Santana [email protected] Coordinadora del Grupo de Convivencia Social y Colombia [email protected] Ministerio de Salud Ciudadanía de la Dirección de Promoción y Prevención Colombia A. Peñuela [email protected] Comoros Ghislaine Mbelu Congo [email protected] Kanyunya Cook Islands Valentino Wichman [email protected] Costa Rica Marchena Vasquez [email protected] Directeur Coordonnateur du Programme National de Côte d’Ivoire Ernest Zotoua [email protected] Lutte contre le Tabagisme, la Toxicomanie et les autres Addictions Croatia Romana Katalinić [email protected] Cuba Cyprus John Kkolos [email protected] Czech Republic Vlastimil Brandejs [email protected] 4 Annex 2 Country Name Focal Point E-mail Affiliation Position Democratic People’s Republic of Korea Democratic Republic of the Congo Denmark Maria Koch Aabel [email protected] Djibouti Dominica Dominican Republic Elizabeth Ruiz [email protected] Francisca Dalia Castillo Dominican Republic [email protected] Sanchez Internal Management of Mental Health and Integral Ecuador Enríquez Anaya [email protected] Prevention of the Socioeconomic Phenomenon of Drugs Area Analyst of the transition process of the “Drugs Ecuador Rojeab Bravo [email protected] Technical Secretariat” into a Ministry of Health attribution Egypt Nahla Attia [email protected] Ministry of Health Egypt José Mauricio Bermúdez El Salvador [email protected] Recinos Equatorial Guinea Eritrea Michael Ghirmai Haile [email protected] Katrin.Tomson- Agency of Medicines of Leading Specialist of Estonia Katrin Tomson-Johanson [email protected] Estonia Department of Inspection Eswatini Drug Dependency Prevention Ethiopia Baharu Zewdie Moya [email protected] and Control 5 Annex 2 Country Name Focal Point E-mail Affiliation Position Medicines Regulatory Authority, Fiji Pharmaceutical & Fiji Ilisabeta May Pesamino [email protected] Chief Pharmacist Biomedical Services Center, Fiji Ministry of Health & Medical Services Finland Katja Pihlainen [email protected] France Aldine Fabreguettes [email protected] Senior Specialist, Gabon Okouyi Ndakissa [email protected] Department of Pharmaceutical Activities Gambia LEPL Regulation Agency for Head of Drug Inspection Georgia Nana Shashiashvili [email protected] Medical and Pharmaceutical Division at the Monitoring Activities Department Germany Annette Viktoria Hinze [email protected] Germany [email protected]). Director, Pharmaceutical Ghana Martha Gyansa-Lutterodt [email protected] Services Greece Ioanna Siamou [email protected] Grenada Departamento de Erica Janeth Cohobon Regulacion y control de Guatemala [email protected] Lepe productos farmeuticos y afines Guinea Guinea-Bissau Guyana Marie Judith Robuste Haiti [email protected] Chef de Service Roche 6 Annex 2 Country Name Focal Point E-mail Affiliation Position Instituto Hondureño para la Alex Virgilio Santos Prevención del Alcoholismo, Honduras [email protected] Director General Moreno Drogadicción y Farmacodependencia Hungary Tímea Kahlesz [email protected] Iceland Bjarni Sigurðsson [email protected] Ministry of Health Pharmacist India Rakesh Chadda [email protected] Dra Agusdini Banun Indonesia [email protected] Saptaningsih Director General of Iran (Islamic Republic of) Ahmad Hajebi [email protected] Ministry of Health department for Mental Health and substance abuse Iran (Islamic Republic of) Alebouyeh [email protected] Iraq Abdulghani [email protected] Assistant Principal, Ireland Brennan [email protected] Department of Health Higher Executive Officer, Ireland Byran Sheehan [email protected] Department of Health Head of Public Health Israel Itamar Grotto [email protected] Ministry of Health Services The Component Authority for Israel Tal Lavy [email protected] Narcotics, Psychotropics, and Precursors Permanent Mission of Israel Israel [email protected] Adviser to the UN, Geneva Directorate General for Italy Pietro Canuzzi, MD [email protected] Health Prevention Italy Rocco Signorile [email protected] Ministry of Health Jamaica Lishann Salmon [email protected] Jamaica Winston De La Haye [email protected] 7 Annex 2 Country Name Focal Point E-mail Affiliation Position Jamaica Michelle Walker [email protected] Japan [email protected] Jordan Heyam Wahbeh [email protected] Kazakhstan Prilutskaya Marina [email protected] Director Pharmacy and Kenya Cheworei Sichey [email protected] Poisons Board Quality Control Laboratory Kenya Simon Njuguna [email protected] Director of Mental Health Kiribati Biribo Kararaiti [email protected] Kuwait Ali Abdulmohsen Jaragh [email protected] Kyrgyzstan Kanyshai Damirbek [email protected] Khatthanaphone Head of Health Promotion Lao People’s Democratic Republic [email protected] Phandoangsy and Nutrition Unit Latvia Linda Veisberga [email protected] Lebanon Marie-Therese Matar [email protected] Lesotho Masello Sello [email protected] Liberia Libya Head of the Drugs and Psychotropic Substances Lithuania Rima Mačiūnienė [email protected] Precursors Control and Risk Assessment Division Luxembourg Alain Origer [email protected] Mahavany Vénot Amélie Madagascar [email protected] Pharmacien Inspecteur Nicole Assistant Director of Malawi Michael Udedi [email protected] Clinical Services (Mental health and substance abuse) 8 Annex 2 Country Name Focal Point E-mail Affiliation Position Senior Principal Assistant Director Licensing Branch Malaysia Rohaida binti Zakaria [email protected] Ministry of Health (Controlled SubSection), Pharmacy Enforcement Division Deputy Director General, Pharmaceuticals; Medicine Maldives Aishath Mohamed [email protected] and Therapeutic Goods Division Ministère de la Santé et des Mali Sékou Oumar Demeble [email protected] Conseiller Technique Affaires Sociales Directeur de la Pharmacie et Mali Yaya Coulibaly [email protected] du Médicament Malta Victor P. Pace [email protected] Marshall Islands Julia Alfred [email protected] Secretary of Health Directeur de la pharmacie et Mauritania Aboubacry amadou BA [email protected] Ministère de la santé des laboratoires Direction de la pharmacie et chef de service Mauritania Mohamed lemine Eddine [email protected] des laboratoires / Ministère de enregistrement la santé Director health Services Mauritius [email protected] (DHS) Mauritius A. Jhugroo [email protected] Adviser, Substance Abuse Verificador- Dictaminador Mexico David Correa Pina [email protected] Especializado Micronesia (Federated States of) Benido Victor [email protected] Monaco Isabelle Kessedjian [email protected] Analyst at Division of Ministry of Health of Mongolia Amarjargal Choijoo [email protected] Pharmaceuticals and Mongolia Medical Devices 9 Annex 2 Country Name Focal Point E-mail Affiliation Position Head of the Department for Montenegro Jasna Sekulic [email protected] prevention policy of drug abuse Morocco Hassan Elkarimi [email protected] Directeur, OMDA, CHU Morocco Jallal Toufiq [email protected] Ar-Razi, Salé Eugénia Guelfrida Salesio Mozambique [email protected] Teodoro Drug Dependency Treatment Program and Research Unit, Myanmar Nanda Myo Aung Wan [email protected] Manager/Consultant Department of Medical Psychiatrist Services Deputy Director(Drugs) / Myanmar Tin Wah Win [email protected] Department of Food and Drug Administration Namibia Ester Mvula [email protected] Nauru Richard Leona [email protected] Nepal Netherlands Liefke Huizinga [email protected] New Zealand Emily Kay [email protected] New Zealand Lauren Bellamore [email protected] Ministry of Health Advisor (Drug Intelligence) Karla Vanessa Delgado Nicaragua [email protected] Martinez Niger Haoua Na Allah Alou [email protected] Nigeria Rafiu Folahan Akanbi [email protected] Niue Grizelda Mokoia [email protected] North Macedonia Anne S. Onsgård Norway [email protected] Sagabråten 10 Annex 2 Country Name Focal Point E-mail Affiliation Position Oman Mahmood Al Abri [email protected] Pakistan Institute of Medical Pakistan Rizwan Taj [email protected] Head of Psychiatry Sciences Islamabad Chief Pharmacist, Chief of Palau Clarette Matlab [email protected] Ancillary Services Palau [email protected] Palau Marla Ito [email protected] Mental Health Program Panama Jose Calderon [email protected] Ministry of Health Chief Papua New Guinea Vicky Wari [email protected] Paraguay Peru Judith Castañeda Alcántara [email protected] Department of Health, Philippines Jose Bienvenido Leabres [email protected] Program Manager Philippines Department of Health, Philippines Clara Fuderanan [email protected] Unit Head Philippines Department of Health, Philippines Carol Narra [email protected] Unit Head Philippines National Bureau for Drug Poland Michał Kidawa [email protected] Prevention General-Directorate for Intervention on Addictive Director of Planning and Portugal Graça Vilar [email protected] Behaviours and Intervention Department Dependencies, Ministry of Health Puerto Rico Qatar Majid Ali Al Abdulla [email protected] Republic of Korea Mi Young Hyun [email protected] 11 Annex 2 Country Name Focal Point E-mail Affiliation Position Pharmaceutical licensing Republic of Moldova Cristina Bogos [email protected] principal specialist activity Chairman of the Standing Medicine and medical devices Republic of Moldova Oleg Costachi [email protected] Committee on Drug agency Control. Romania Camelia Bunaciu [email protected] Russian Federation Olga Panova [email protected] Rwanda Saint Kitts and Nevis Saint Lucia Donna Daniel [email protected] Programme Officer, Substance Abuse Unit, Saint Lucia Paul Caleb [email protected] Department of Health and Wellness Saint Vincent and the Grenadines Samoa Robert Thomsen [email protected] San Marino Gabriele Rinaldi [email protected] Health Authority Director San Marino Andrea Gualtieri [email protected] Health Authority MD Sao Tome and Principe Saudi Food and Drug Saudi Arabia Adnan Alshammary [email protected] Authority Senegal Bintou Dia [email protected] Serbia Nataša Savić [email protected] Seychelles Sierra Leone 12 Annex 2 Country Name Focal Point E-mail Affiliation Position Senior Executive Singapore Ong Lay Tin [email protected] Ministry of Health (International Cooperation) / Public Health Group Department of Drug Strategy Coordination and Monitoring Coordinator of the Slovak Slovakia Peter Koren [email protected] of Drugs, Ministry of Health EWS, Reitox National FP of the Slovak Republic Slovenia Joze Hren [email protected] Solomon Islands Paul Orotaloa [email protected] Solomon Islands Stephen Araitewa [email protected] Somalia Deputy Director South Africa MG Molewa [email protected] Inspectorate & Law Enforcement South Sudan Agencia Española de Jefe de Departamento de Spain Manuel Ibarra [email protected] Medicamentos y Productos Inspección y Control de Sanitarios Medicamento Agencia Española de Jefe del Área de Spain Lidia Fernandez Matellano [email protected] Medicamentos y Productos Estupefacientes y Sanitarios Psicótropos Sri Lanka BMW Balasooriya [email protected] Sudan Suriname Sweden David Lorentzon [email protected] Switzerland Diane Steber [email protected] Syrian Arab Republic Ahmed Al-Salama [email protected] Directorate of Mental Health Tajikistan Salim Abdulazizov [email protected] 13 Annex 2 Country Name Focal Point E-mail Affiliation Position Narcotics Control Division (Standards and Regulations Pharmacist in Professional Thailand Chantharakul [email protected] Sub-Division), Food And Level Drug Administration, Ministry of Public Narcotics Control Division (Standards and Regulations Pharmacist in Professional Thailand Chavanich [email protected] Sub-Division), Food And Level Drug Administration, Ministry of Public Narcotics Control Division, Food And Drug Director of Narcotics Thailand Tontisirin [email protected] Administration, Ministry of Control Division Public Health Official at the Department National Directorate for Timor-Leste Soares Henriques [email protected] of Authorisation and Pharmacy and Medicine Markets Introduction Togo Afèignindou Gnassingbe [email protected] Togo Tonga Melenaite Mahe [email protected] Trinidad and Tobago Rohit Doon [email protected] Tunisia Head of Department for Pharmacovigilance and the Turkey Demet Aydınkarahaliloğlu [email protected] Substances subject to control Turkmenistan Tuvalu Uganda Hafsa Lukwata [email protected] Senior Medical Officer 14 Annex 2 Country Name Focal Point E-mail Affiliation Position Deputy Director of the State Agency “The Center for Ukraine Liudmyla Konoshevych [email protected] Ministry of Health of Ukraine Mental Health Monitoring of Drugs and Alcohol” Head of the Department of National Strategy and Policy on the Circulation of Psychoactive Substances of Ukraine Viktoria Kurlova [email protected] Ministry of Health of Ukraine the State Agency “Center for Mental Health Monitoring of Drugs and Alcohol” the State Agency “The Center for Mental Health Ukraine Sergii Shum [email protected] Ministry of Health of Ukraine Monitoring of Drugs and Alcohol” United Arab Emirates United Kingdom of Great Britain Catherine Crawford [email protected] Public Health England Head of Focal Point and Northern Ireland United Kingdom of Great Britain Alberto Oteo [email protected] Public Health England Project manager and Northern Ireland United Republic of Tanzania Sara Maongezi [email protected] Center for Drug Evaluation & Senior Program Manager United States of America Jim Hunter [email protected] Research Controlled Substances Area programatica de salud Uruguay Horacio Porciuncula [email protected] mental Uzbekistan Vanuatu Jerry Iaruel [email protected] Venezuela (Bolivarian Republic of) 15 Annex 2 Country Name Focal Point E-mail Affiliation Position Head of Prevention Department, Viet Nam Viet Nam Mhin Tam Nguyen [email protected] Ministry of Health Authority for HIV/AIDS Control Yemen Zambia Nita Besa [email protected] Head of department mental Deputy Director Mental Zimbabwe Sacrifice Chirisa [email protected] Health Services Head office Health = = = 16 Saatja: <[email protected]> Saadetud: 14.06.2021 10:00 Koopia: <[email protected]> Teema: WHO: C.L.20.2021 (44th ECDD) Dear Member States of the World Health Organization,Please find attached, in the six official languages, C.L.20.2021 regarding the 44th Expert Committee on Drug Dependence (ECDD) which will meet from 11 to 15 October 2021.Should you have questions regarding C.L.20.2021 please send an email to [email protected] regards,Department of Governing BodiesWorld Health Organization
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel